← Ablatotech Vitals
GeriatricMedicine EvidenceDigest

Clinical evidence and management strategies for optimizing deprescribing of benzodiazepines in older adults with anxiety and insomnia

GeriatricMedicine · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 17, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Deprescribing benzodiazepines in older adults with anxiety and insomnia is a critical strategy to reduce risks of cognitive impairment, falls, and dependence. Evidence supports gradual tapering combined with patient education and non-pharmacologic interventions such as cognitive-behavioral therapy for insomnia (CBT-I). Pharmacist-led and interdisciplinary approaches enhance deprescribing success. Despite challenges, tailored deprescribing protocols improve safety and quality of life in this vulnerable population.

Clinical bottom line

Deprescribing benzodiazepines in older adults with anxiety and insomnia is a critical strategy to reduce risks of cognitive impairment, falls, and dependence. Evidence supports gradual tapering combined with patient education and non-pharmacologic interventions such as cognitive-behavioral therapy for insomnia (CBT-I). Pharmacist-led and interdisciplinary approaches enhance deprescribing success. Despite challenges, tailored deprescribing protocols improve safety and quality of life in this vulnerable population.

What the evidence shows

Benzodiazepines remain commonly prescribed for anxiety and insomnia in older adults despite well-documented risks. Pishock et al. (2022) emphasize that deprescribing benzodiazepines reduces adverse outcomes including sedation, falls, and cognitive decline, and is feasible with structured tapering protocols.

Gerlach et al. (2025) highlight clinical considerations specific to older adults, recommending slow dose reductions individualized to patient tolerance and comorbidities. They also underscore the importance of addressing underlying anxiety or insomnia with safer alternatives.

Hughes et al. (2024) demonstrated that pharmacist-led deprescribing interventions in older adults significantly increased benzodiazepine discontinuation rates, facilitated by medication reviews, patient counseling, and coordination with prescribers.

Patient perceptions influence deprescribing success; Choi et al. (2021) found that older adults often fear symptom recurrence but respond well to clear communication about risks and benefits, reinforcing the need for shared decision-making.

Non-pharmacologic treatments, particularly CBT-I, have robust evidence for managing insomnia in older adults and support benzodiazepine tapering (Dillon et al., 2012). Hung et al. (2022) advocate for integrating behavioral therapies in both community and nursing home settings to optimize deprescribing outcomes.

Garfinkel et al. (2026) discuss broader polypharmacy challenges, recommending deprescribing as part of comprehensive medication management to improve overall patient safety.

Caveats and uncertainty

Deprescribing benzodiazepines can be complicated by withdrawal symptoms and underlying psychiatric conditions requiring careful monitoring.

There is variability in tapering protocols and no universally accepted standard, necessitating individualized approaches.

Access to behavioral therapies like CBT-I may be limited by resource constraints.

Long-term outcomes of deprescribing interventions on anxiety and insomnia control require further study.

Patient adherence and provider engagement remain barriers to widespread implementation.

How this may change practice

Clinicians should proactively identify older adults on benzodiazepines and initiate deprescribing discussions emphasizing risks and alternatives.

Implementing gradual, patient-centered tapering protocols supported by education and behavioral therapies can improve success rates.

Pharmacist involvement and interdisciplinary collaboration are valuable for medication review and deprescribing support.

Routine incorporation of non-pharmacologic treatments for anxiety and insomnia should be prioritized to sustain deprescribing gains.

Healthcare systems should invest in training and resources to facilitate deprescribing and behavioral interventions in geriatric populations.


References

  1. Pishock RA, et al. Deprescribing Benzodiazepines in Older Adults. Nursing & Primary Care. 2022; DOI:10.33425/2639-9474.1213
  2. Gerlach LB, et al. Benzodiazepines and BRAs in Older Adults: Clinical Considerations. 2025; DOI:10.64239/pi-vl9609
  3. Hughes TD, et al. Pharmacist-Led Deprescribing of Opioids and Benzodiazepines in Older Adults: Examining Implementation and Perceptions. Pharmacy. 2024; DOI:10.3390/pharmacy12040119
  4. Choi J, et al. Older adults’ perceptions of deprescribing chronic benzodiazepines. Journal of the American Pharmacists Association. 2021; DOI:10.1016/j.japh.2021.04.003
  5. Dillon HR, et al. Evidence-based treatments for insomnia in older adults. Making evidence-based psychological treatments work with older adults. 2012; DOI:10.1037/13753-003
  6. Hung, et al. Deprescribing in Older Adults in Community and Nursing Home Settings. Journal of Clinical Outcomes Management. 2022; DOI:10.12788/jcom.0112
  7. Garfinkel D, et al. Editorial: Optimizing medication management in older adults: addressing polypharmacy, deprescribing and represcribing challenges. Frontiers in Medicine. 2026; DOI:10.3389/fmed.2026.1824505

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team